ADME characterization and PBK model development of 3 highly protein-bound UV filters through topical application.


Journal

Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929
Titre abrégé: Toxicol Sci
Pays: United States
ID NLM: 9805461

Informations de publication

Date de publication:
30 Oct 2023
Historique:
medline: 31 10 2023
pubmed: 16 8 2023
entrez: 16 8 2023
Statut: ppublish

Résumé

Estimating human exposure in the safety assessment of chemicals is crucial. Physiologically based kinetic (PBK) models which combine information on exposure, physiology, and chemical properties, describing the absorption, distribution, metabolism, and excretion (ADME) processes of a chemical, can be used to calculate internal exposure metrics such as maximum concentration and area under the concentration-time curve in plasma or tissues of a test chemical in next-generation risk assessment. This article demonstrates the development of PBK models for 3 UV filters, specifically octyl methoxycinnamate, octocrylene, and 4-methylbenzylidene camphor. The models were parameterized entirely based on data obtained from in vitro and/or in silico methods in a bottom-up modeling approach and then validated based on human dermal pharmacokinetic (PK) data. The 3 UV filters are "difficult to test" in in vitro test systems due to high lipophilicity, high binding affinity for proteins, and nonspecific binding, for example, toward plastic. This research work presents critical considerations in ADME data generation, interpretation, and parameterization to assure valid PBK model development to increase confidence in using PBK modeling to help make safety decisions in the absence of human PK data. The developed PBK models of the 3 chemicals successfully simulated the plasma concentration profiles of clinical PK data following dermal application, indicating the reliability of the ADME data generated and the parameters determined. The study also provides insights and lessons learned for characterizing ADME and developing PBK models for highly lipophilic and protein-bound chemicals in the future.

Identifiants

pubmed: 37584694
pii: 7243196
doi: 10.1093/toxsci/kfad081
pmc: PMC10613959
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-15

Subventions

Organisme : Cosmetics Europe Long Range Science Strategy

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Society of Toxicology.

Références

Anal Chem. 2023 Feb 28;95(8):4086-4094
pubmed: 36791153
Toxicol Lett. 1995 Sep;79(1-3):35-44
pubmed: 7570672
Environ Monit Assess. 1994 Sep;32(2):135-54
pubmed: 24214086
Mol Nutr Food Res. 2011 Jun;55(6):941-56
pubmed: 21520492
J Pharm Sci. 2004 Jun;93(6):1628-40
pubmed: 15124219
Toxicol Appl Pharmacol. 2022 May 1;442:115992
pubmed: 35346730
J Pharm Sci. 2021 Apr;110(4):1799-1823
pubmed: 33338491
Comput Toxicol. 2019 Feb;9:61-72
pubmed: 31008414
Drug Metab Dispos. 2007 Oct;35(10):1766-80
pubmed: 17620347
Toxicol In Vitro. 2020 Mar;63:104746
pubmed: 31837441
Regul Toxicol Pharmacol. 2021 Dec;127:105052
pubmed: 34653552
Postgrad Med J. 1976;52 Suppl 4:22-25
pubmed: 787953
Drug Metab Pharmacokinet. 2009;24(1):53-75
pubmed: 19252336
Cancer Chemother Pharmacol. 1979;2(2):85-94
pubmed: 93986
Toxicol In Vitro. 2020 Mar;63:104722
pubmed: 31756541
Toxicol In Vitro. 2021 Aug;74:105171
pubmed: 33848589
Pharm Res. 2015 Dec;32(12):3785-802
pubmed: 26155985
J Pharm Sci. 2021 Jul;110(7):2841-2858
pubmed: 33857483
J Pharm Sci. 2019 Mar;108(3):1296-1302
pubmed: 30326208
J Pharmacokinet Biopharm. 1977 Dec;5(6):625-53
pubmed: 599411
Sci Rep. 2015 Oct 13;5:14866
pubmed: 26460813
Protein Sci. 2002 May;11(5):1017-25
pubmed: 11967359
J Pharmacokinet Biopharm. 1979 Apr;7(2):127-45
pubmed: 20218010
Xenobiotica. 2007 Oct-Nov;37(10-11):1110-34
pubmed: 17968739
Anal Chem. 2008 Apr 15;80(8):2993-9
pubmed: 18355058
J Pharm Sci. 2015 Aug;104(8):2627-36
pubmed: 26037784
Mol Pharm. 2019 Sep 3;16(9):4077-4085
pubmed: 31348668
Drug Metab Dispos. 1999 Nov;27(11):1350-9
pubmed: 10534321
Clin Pharmacol Ther. 2015 Mar;97(3):247-62
pubmed: 25670209
JAMA. 2019 Jun 4;321(21):2082-2091
pubmed: 31058986
Toxicol Appl Pharmacol. 2006 Oct 15;216(2):339-46
pubmed: 16814339
Curr Drug Metab. 2008 Nov;9(9):854-9
pubmed: 18991581
Biochem Soc Trans. 1990 Dec;18(6):1198-9
pubmed: 1982435
J Pharm Sci. 2014 Feb;103(2):752-9
pubmed: 24375113
Toxicol In Vitro. 1994 Aug;8(4):507-12
pubmed: 20692946
J Pharm Biomed Anal. 2006 Apr 11;41(1):299-303
pubmed: 16314065

Auteurs

Hequn Li (H)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Fazila Bunglawala (F)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Nicola J Hewitt (NJ)

Cosmetics Europe, Auderghem 1160, Belgium.

Ruth Pendlington (R)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Richard Cubberley (R)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Beate Nicol (B)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Sandrine Spriggs (S)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Maria Baltazar (M)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Sophie Cable (S)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Matthew Dent (M)

Unilever Safety and Environmental Assurance Centre, Sharnbrook MK44 1LQ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH